Polymorphic CYP2C19 and N-acetylation: Human variability in kinetics and pathway-related uncertainty factors

Food and Chemical Toxicology

Volumn 41, Issue 2, 2003, Pages 225-245

  Dorne, J L C M ^a,b   Walton, K ^a   Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

CYP2C19; Human variability; N acetylation; Pharmacokinetics; Risk assessment; Sensitive subgroups; Uncertainty factors

Indexed keywords

BARBITURIC ACID DERIVATIVE; CYTOCHROME P450 2C19; DIAZEPAM; HEXOBARBITAL; ISONIAZID; MEPHENYTOIN; OMEPRAZOLE; PROGUANIL; SULFADIMIDINE;

AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NORMAL HUMAN; PHENOTYPE;

ACETYLATION; ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; DATABASES; HUMANS; INJECTIONS, INTRAVENOUS; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; UNCERTAINTY; XENOBIOTICS;

EID: 0037290590     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(02)00210-7     Document Type: Article

References (84)

1. Adedoyin A., Prakash C., O'Shea D., Blair I.A., Wilkinson G.R. Stereoselective disposition of hexobarbital and its metabolites. relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects Pharmacogenetics. 4:1994;27-38.
2. Adedoyin A., Richards W.O., Wilkinson G.R., Branch R.A. Selective effect of liver disease on the activities of specific metabolizing enzymes. investigation of cytochromes P450 2C19 and 2D6 Clinical Pharmacology and Therapeutics. 64:1998;8-17.
3. Advenier C., Saint A.A., Gobert C., Houin G., Albengres E., Tillement J.P. Pharmacokinetics of isoniazid in the elderly [letter]. British Journal of Clinical Pharmacology. 10:1980;167-169.
4. Advenier C., Saint-Aubin A., Scheinmann P., Paupe J. Pharmacokinetics of isoniazid in children. Revue Francaise des Maladies Respiratoires. 9:1981;365-374.
5. Aitchison J., Brown J.A.C. The Lognormal Distribution. 1966;University Press, Cambridge.
6. Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics. 47:1990;79-85.
7. Andersson T., Cederberg C., Regardh C.G., Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology. 39:1990;195-197.
8. Andersson T., Hassall E., Lundborg P., Shepherd R., Radke M., Marcon M., Dalvag A., Martin S., Behrens R., Koletzko S., Becker M., Drouin E., Gothberg G. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group (2000). American Journal of Gastroenterology. 95:2000;3101-3106.
9. Andersson T., Holmberg J., Rohss K., Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. British Journal of Clinical Pharmacology. 45:1998;369-375.
10. Andersson T., Miners J.O., Veronese M.E., Birkett D.J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology. 38:1994;131-137.
11. Andersson T., Olsson R., Regardh C.G., Skanberg I. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clinical Pharmacokinetics. 24:1993;71-78.
12. Andersson T., Regardh C.G., Lou Y.C., Zhang Y., Dahl M.L., Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 2:1992;25-31.
13. Bertilsson L., Henthorn T.K., Sanz E., Tybring G., Sawe J., Villen T. Importance of genetic factors in the regulation of diazepam metabolism. relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype Clinical Pharmacology and Therapeutics. 45:1989;348-355.
14. Bertilsson L., Tybring G., Widen J., Chang M., Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. British Journal of Clinical Pharmacology. 44:1997;186-189.
15. Bottiger Y., Tybring G., Gotharson E., Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics. 62:1997;384-391.
16. Breimer D.D., Zilly W., Richter E. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Clinical Pharmacology and Therapeutics. 18:1975;433-440.
17. Birkett D.J., Rees D., Andersson T., Gonzalez F.J., Miners J.O., Veronese M.E. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. British Journal of Clinical Pharmacology. 37:1994;413-420.
18. Chandler M.H., Scott S.R., Blouin R.A. Age-associated stereoselective alterations in hexobarbital metabolism. Clinical Pharmacology and Therapeutics. 43:1988;436-441.
19. Chang M., Dahl M.L., Tybring G., Gotharson E., Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians. comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics. 5:1995;358-363.
20. Chang M., Tybring G., Dahl M.L., Gotharson E., Sagar M., Seensalu R., Bertilsson L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. British Journal of Clinical Pharmacology. 39:1995;511-518.
21. Chapron D.J., Kramer P.A., Mercik S.A. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clinical Pharmacology and Therapeutics. 27:1979;104-113.
22. Ching M.S., Mihaly G.W., Angus P.W., Morgan D.J., Devenish M.S., Yeomans N.D., Smallwood R.A. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. British Journal of Clinical Pharmacology. 31:1991;166-170.
23. Dorne J.L.C.M., Walton K., Renwick A.G. Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates Food and Chemical Toxicology. 39:2001;681-696.
24. Dorne J.L.C.M., Walton K., Renwick A.G. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food and Chemical Toxicology. 39:2001;1153-1173.
25. Dorne, J.L.C.M., Walton, K., Slob, W., Renwick, A.G., 2002a. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and Chemical Toxicology 40, 1633-1656.
26. Dorne, J.L.C.M., Walton, K., Renwick, A.G., 2002b. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 40 This issue.
27. Duvauchelle T., Millerioux L., Gualano V., Evene E., Alcaide A. Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers. Clinical Drug Investigation. 16:1998;141-149.
28. Furuta T., Ohashi K., Kosuge K., Zhao X.J., Takashima M., Kimura M., Nishimoto M., Hanai H., Kaneko E., Ishizaki T. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clinical Pharmacology and Therapeutics. 65:1999;552-561.
29. Hattis D., Minkowitz W.S. Risk evaluation. criteria arising from legal traditions and experience with quantitative risk assessment in the United States Environmental Toxicology and Pharmacology. 2:1996;103-109.
30. Hayes J.D., McLellon L.I. Glutathione and glutathion-dependent enzymes represent a coordinately regulated defense against oxidative stress. Free Radical Research. 31:1999;273-300.
31. Helsby N.A., Ward S.A., Edwards G., Howells R.E., Breckenridge A.M. The pharmacokinetics and activation of proguanil in man. consequences of variability in drug metabolism British Journal of Clinical Pharmacology. 30:1990;593-598.
32. Horai Y., Ishizaki T., Sasaki T., Koya G., Matsuyama K., Iguchi S. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects. British Journal of Clinical Pharmacology. 13:1982;361-374.
33. Howden C.W., Reid J.L. The effect of antacids and metoclopramide on omeprazole absorption and disposition. British Journal of Clinical Pharmacology. 25:1988;779-781.
34. IPCS (International Programme on Chemical Safety), 1994. Assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits. Environmental Health Criteria, Vol. 170, World Health Organization, International Programme on Chemical Safety, Geneva.
35. IPCS (International Programme on Chemical Safety), 1999. Principles for the assessment of risk to human health from exposure to chemicals. Environmental Health Criteria, Vol. 210, World Health Organization, Geneva.
36. Jacqz-Aigrain E., Bellaich M., Faure C., Andre J., Rohlrich P., Baudouin V., Navarro J. Pharmacokinetics of intravenous omeprazole in children. European Journal of Clinical Pharmacology. 47:1994;181-185.
37. Jansen J.B.M.J., Lundborg P., Baak L.C., Greve J., Ohman M., Stover C., Rohss K., Lamers B.H.W. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated secretion and pharmacokinetics in man. Gut. 29:1988;75-80.
38. Jeppesen U., Buur R.B., Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clinical Pharmacology and Therapeutics. 62:1997;279-286.
39. Johnson J.A. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. International Journal of Clinical Pharmacology and Therapeutics. 38:2000;53-60.
40. Karam W.G., Goldstein J.A., Lasker J.M., Ghanayem B.I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition. 24:1996;1081-1087.
41. Kergueris M.F., Bourin M., Larousse C. Pharmacokinetics of isoniazid. influence of age European Journal of Clinical Pharmacology. 30:1986;335-340.
42. Kergueris M.F., Larousse C., Le N.Y., Bourin M. Acetylation character of isoniazid in the rabbit and in man. European Journal of Drug Metabolism and Pharmacokinetics. 8:1983;133-136.
43. Kupfer A., Roberts R.K., Schenker S., Branch R.A. Stereoselective metabolism of mephenytoin in man. Journal of Pharmacology and Experimental Therapeutics. 218:1981;193-199.
44. Land S.J., Zukowski K., Lee M.S., Debiec-Rychter M., King C.M., Wang C.Y. Metabolism of aromatic amines. relationships of N-acetylation, O-acetylation, N,O-acetyltransfer and deacetylation in human liver and urinary bladder Carcinogenesis. 10:1989;727-731.
45. Lee E.J.D., Lee L.K.H. A simple pharmacokinetic method for separating the three acetylation phenotypes. a preliminary report British Journal of Clinical Pharmacology. 13:1982;375-378.
46. Lin H.J., Han C.Y., Lin B.K., Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites. application to metabolic epidemiology American Journal of Human Genetics. 52:1993;827-834.
47. Lind T., Andersson T., Skanberg I., Olbe L. Biliary excretion of intravenous [14C] omeprazole in humans. Clinical Pharmacology and Therapeutics. 42:1987;504-508.
48. Maegraith B.G., Toottey M.M., Adams A.R.D., Horner Andrews W.H., King J.D. The absorption and excretion of paludrine in the human subject. Annals of Tropical Medecine and Parasitology. 40:1946;493-506.
49. McKee R.F., MacGilchrist A.J., Garden O.J., Forrest J.A., Carter D.C. The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease. Alimentary Pharmacology and Therapeutics. 2:1988;429-437.
50. Meyer U.A. Polymorphism of human acetyltransferases. Environmental Health Perspectives. 102(Suppl 6):1994;213-216.
51. Naesdal J., Andersson T., Bodemar G., Larsson R., Regardh C.G., Skanberg I., Walan A. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clinical Pharmacology and Therapeutics. 40:1986;344-351.
52. Naumann B.D., Weidemann P.A. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Human and Ecological Risk Assessment. 1:1995;590-613.
53. Naumann B.D., Weidemann P.A., Dixit R., Grossman S.J., Shen C.F., Sargent E. V, Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Human and Ecological Risk Assessment. 3:1997;555-565.
54. Olson W., Micelli J., Weber W. Dose-dependent changes in sulphamethazine kinetics in rapid and slow isoniazid acetylators. Clinical Pharmacology and Therapeutics. 23:1978;204-211.
55. Peloquin C.A., James G.T., Craig L.D., Kim M., McCarthy E.A., Ikle D., Iseman M.D. Pharmacokinetics evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Pharmacotherapy. 14:1994;415-423.
56. Pillai G.K., Hassan M.M., Sheikh Salem M., Najib N.M. Effect of food on the bioavailability of omeprazole. International Journal of Pharmaceutical Medicine. 12:1998;199-203.
57. Regardh C.G., Andersson T., Lagerstrom P.O., Lundborg P., Skanberg I. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Therapeutic Drug Monitoring. 12:1990;163-172.
58. Renberg L., Simonsson R., Hoffmann K.J. Identification of two main urinary metabolites of [14C]omeprazole in humans. Drug Metabolism and Disposition. 17:1989;69-76.
59. Renwick A.G. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Additives and Contaminants. 10:1993;275-305.
60. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regulatory Toxicology and Pharmacology. 27:1998;3-20.
61. Richter E., Breimer D.D., Zilly W. Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. European Journal of Clinical Pharmacology. 17:1980;197-202.
62. Rinetti M., Regazzi M.B., Villani P., Tizzoni M., Sivelli R. Pharmacokinetics of omeprazole in cirrhotic patients. Arzneimittelforschung. 41:1991;420-422.
63. Sakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., Hohda T., Sirasaka D., Tamura T., Tanigawara Y., Kasuga M., Okumura K. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharmaceutical Research. 18:2001;721-727.
64. Setiabudy R., Kusaka M., Chiba K., Darmansjah I., Ishizaki T. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. British Journal of Clinical Pharmacology. 39:1995;297-303.
65. Shimada T., Misono K.S., Guengerich F.P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. Journal of Biological Chemistry. 261:1986;909-921.
66. Siegmund W., Franke G., Baumgarten R., Fengler J.D., Kruger R., Reichardt R. Kinetics of antipyrine and sulfamethazine in patients recovered from dihydralazine-hepatitis. International Journal of Clinical Pharmacology, Therapy and Toxicology. 27:1989;165-169.
67. Siegmund W., Franke G., Wulkow R., Hanke W., Thonack R. N-acetylation and oxidative capacity in aged volunteers determined with sulphamethazine and antipyrine. International Journal of Clinical Pharmacology, Therapy and Toxicology. 29:1991;469-473.
68. Sohn D.R., Kobayashi K., Chiba K., Lee K.H., Shin S.G., Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. Journal of Pharmacology and Experimental Therapeutics. 262:1992;1195-1202.
69. Sohn D.R., Kusaka M., Ishizaki T., Shin S.G., Jang I.J., Shin J.G., Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clinical Pharmacology and Therapeutics. 52:1992;160-169.
70. Somogyi A.A., Reinhard H.A., Bochner F. Pharmacokinetic evaluation of proguanil. a probe phenotyping drug for the mephenytoin hydroxylase polymorphism British Journal of Clinical Pharmacology. 22:1996;401-408.
71. Stresser D.M., Kupfer D. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation. Drug Metabolism and Disposition. 26:1998;868-874.
72. Suhardjono D., Boutagy J., Shenfield G.M. The effect of glucose on acetylation status. British Journal of Clinical Pharmacology. 22:1986;401-408.
73. Tang J., Cao Y., Rose R.L., Brimfield A.A., Dai D., Goldstein J.A., Hodgson E. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metabolism and Disposition. 29:2001;1201-1204.
74. Thoring M., Hedenstrom H., Eriksson L.S. Rapid effect of lansoprazole on intragastric pH. a crossover comparison with omeprazole Scandinavian Journal of Gastroenterology. 34:1999;341-345.
75. Van der Graff M., Vermeulen N.P., Heij P., Boeijinga J.K., Breimer D.D. Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. Biopharmaceutics and Drug Disposition. 7:1986;265-272.
76. Vinayek R., Amantea M.A., Maton P.N., Frucht H., Gardner J.D., Jensen R.T. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology. 101:1991;138-147.
77. Wan J., Xia H., He N., Lu Y.Q., Zhou H.H. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. British Journal of Clinical Pharmacology. 42:1996;471-474.
78. Wedlund P.J., Aslanian W.S., Jacqz E., McAllister C.B., Branch R.A., Wilkinson G.R. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. Journal of Pharmacology and Experimental Therapeutics. 234:1985;662-669.
79. Wedlund P.J. The CYP2C19 enzyme polymorphism. Pharmacology. 61:2000;174-183.
80. WHO, 1987. Principles for the assessment of risk to human health from exposure to chemicals. Environmental Health Criteria Vol. 70, World Health Organization, Geneva.
81. Yasuda S., Horai Y., Tomono Y., Nakai H., Yamato C., Manabe K., Kobayashi K., Chiba K., Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clinical Pharmacology and Therapeutics. 58:1995;143-154.
82. Zhang Y., Reviriego J., Lou Y., Sjoqvist F., Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin. interethnic differences in comparison with white subjects Clinical Pharmacology and Therapeutics. 48:1990;496-502.
83. Zilly W., Breimer D.D., Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. European Journal of Clinical Pharmacology. 9:1975;219-227.
84. Zilly W., Richter E. (Drug clearance as a decision aid for further invasive liver diagnosis - studies with hexobarbital as a model substrate) Die Arzneimittelclearance als Entscheidungshilfe fur eine weiterfuhrende invasive Leberdiagnostik - Untersuchungen mit Hexobarbital als Modellsubstrat. Zeitschrift Fur Gastroenterologie. 30:1992;325-328.